Stocklytics Platform
Asset logo for symbol XENE
Xenon Pharmaceuticals
XENE58
$43.96arrow_drop_up0.25%$0.11
Asset logo for symbol XENE
XENE58

$43.96

arrow_drop_up0.25%

Performance History

Chart placeholder
Key Stats
Open$43.98
Prev. Close$43.73
EPS-2.72
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range43.47
44.34
52 Week Range27.98
50.99
Ratios
Revenue-
EBITDA Margin %-
EPS-2.72

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals Inc. (XENE) is a pharmaceutical company focused on the discovery and development of innovative therapeutics for neurological disorders. The company's primary objective is to improve the lives of patients suffering from diseases such as epilepsy, migraine, and Alzheimer's. With a strong emphasis on precision medicine, Xenon utilizes its proprietary drug discovery platform to identify and target specific genetic variations that play a role in these disorders.
Xenon's stock price history reflects the company's commitment to scientific excellence and innovation. Over the years, the stock has shown significant growth, driven by positive clinical trial results and successful partnerships. Investors have recognized the potential of Xenon's pipeline of novel therapeutics, leading to a continuous increase in the stock price.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Headquarters
Burnaby
Employees
203
Exchange
NASDAQ
add Xenon Pharmaceuticals to watchlist

Keep an eye on Xenon Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Xenon Pharmaceuticals 's (XENE) price per share?
The current price per share for Xenon Pharmaceuticals (XENE) is $43.96. The stock has seen a price change of $0.11 recently, indicating a 0.25% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Xenon Pharmaceuticals (XENE)?
For Xenon Pharmaceuticals (XENE), the 52-week high is $50.99, which is 15.99% from the current price. The 52-week low is $27.98, the current price is 57.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Xenon Pharmaceuticals (XENE) a growth stock?
Xenon Pharmaceuticals (XENE) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Xenon Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Xenon Pharmaceuticals (XENE) stock price performance year to date (YTD)?
As of the latest data, Xenon Pharmaceuticals (XENE) has a year-to-date price change of -2.12%. Over the past month, the stock has experienced a price change of 18.81%. Over the last three months, the change has been 9.63%. Over the past six months, the figure is -2.64%. Looking at a longer horizon, the five-year price change stands at 358.87%.
help
Is Xenon Pharmaceuticals (XENE) a profitable company?
Xenon Pharmaceuticals (XENE) has a net income of -$182.39M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$214.05M. Furthermore, the EBITDA is -$220.26M.
help
What is the market capitalization of Xenon Pharmaceuticals (XENE)?
Xenon Pharmaceuticals (XENE) has a market capitalization of $3.32B. The average daily trading volume is 405.36K, indicating the stock's liquidity and investor engagement.

News

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
7/2/2024

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
CALENDAR OF EVENTS
CLINICAL STUDY
5/28/2024

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
5/10/2024

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
EARNINGS RELEASES AND OPERATING RESULTS
5/9/2024

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
CALENDAR OF EVENTS
CONFERENCE CALLS/ WEBCASTS
5/8/2024

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
CONFERENCE CALLS/ WEBCASTS
5/7/2024

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level